In the early AIDS trial of zidovudine (AZT), how many men died while receiving the drug?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Deaths in Early AZT Trials

In the landmark 1987 placebo-controlled trial of AZT (BW 002/ACTG 002), 1 patient died in the AZT group compared to 19 deaths in the placebo group during the study period 1.

Trial Details and Mortality Data

The pivotal double-blind, placebo-controlled trial enrolled 282 patients with AIDS (manifested by Pneumocystis carinii pneumonia) or advanced AIDS-related complex 1. Patients were randomized to receive either:

  • AZT group: 250 mg every 4 hours orally (n=145)
  • Placebo group: (n=137)

Primary Mortality Findings

The mortality difference was striking and statistically significant (P <0.001):

  • AZT recipients: 1 death
  • Placebo recipients: 19 deaths

This dramatic survival benefit led to early termination of the trial 1. The study duration varied by patient, with 27 subjects completing 24 weeks, 152 completing 16 weeks, and the remainder completing at least 8 weeks.

Additional Clinical Benefits Beyond Mortality

Beyond the mortality reduction, AZT demonstrated:

  • Reduced opportunistic infections: 24 infections in AZT group vs 45 in placebo group
  • Improved functional status: Significant increases in Karnofsky performance scores (P <0.001)
  • Weight gain: Statistically significant improvement (P <0.001)
  • Immunologic improvement: Significant CD4 cell count increases (P <0.001), though this effect declined after 12 weeks in AIDS patients
  • Partial reversal of anergy: 29% of AZT recipients vs 9% of placebo recipients (P <0.001)

Important Context

The FDA label confirms that "therapy with zidovudine has been shown to prolong survival and decrease the incidence of opportunistic infections in patients with advanced HIV-1 disease" 2. However, the label also notes that "a survival benefit for monotherapy with zidovudine was not demonstrated" in subsequent trials of asymptomatic or mildly symptomatic patients (ACTG 016 and ACTG 019), and that "subsequent trials showed that the clinical benefit of monotherapy with zidovudine was time limited" 2.

Critical Caveat

AZT monotherapy is no longer recommended or used in clinical practice. Modern HIV treatment requires combination antiretroviral therapy (ART). When used in combination regimens, zidovudine continues to demonstrate efficacy in reducing mortality and disease progression 2.

The question's premise about "progression-free survival not guaranteeing living longer" is contradicted by the early trial data, which showed clear mortality benefit in advanced AIDS patients receiving AZT versus placebo.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.